RU1811404C - Zoonotic dermal leishmaniasis treatment method - Google Patents

Abstract

The invention relates to medicine, in particular to the treatment of zoonoses. The goal is to reduce treatment time with the exclusion of antibiotic therapy. For this, T-activin is used in the treatment of zoonotic cutaneous leishmaniasis, which is introduced in the form of a 0.01% solution of 1 ml into the zone located between the regional lymph nodes of the area of the main skin lesions.

Description

The invention relates to medicine and can be used in the treatment of zoonotic diseases, in particular zoonotic cutaneous leishmaniasis.

The purpose of the invention is to shorten treatment time with the exception of antibiotic therapy.

The treatment method is characterized in that a 0.01% solution of T-activin is used as a therapeutic agent. Subcutaneous injection is carried out in a single dose of 1.0 ml (for adults) after 1 day in the middle zone between the regional lymph nodes, to which the main skin lesions are adjacent. The course of treatment is 5-10 injections. In the presence of a relatively small size of single leishmaniomas that are not accompanied by complications in the form of multiple nodular lymphangitis, seeding tubercles, microabscesses, as well as the attachment of a bacterial-pyococcal infection, 7 injections are sufficient. In some patients with a relatively mild course of a specific process, the amount

Tactivin injections can be limited to 4-5, otherwise the number of injections is adjusted to 10.

Example 1. Sick for 20 years. She was admitted to the hospital of the Turkmen Republican Dermatovenerologic Dispensary with complaints of gnosis. The duration of the disease is -2 months. Objectively: in the region of the upper third of the right forearm there is an ulcer 2.0x2.0 cm in diameter, shallow, the bottom is lined with a laden granulation tissue, separated-serous-purulent, scanty. In the region of marginal infiltrate there are many seedlings and microabscesses. Diagnosis: zoonotic cutaneous leishmaniasis in the initial scarring stage, complicated by multiple seedling tubercles and microabscesses. Treatment: 1. T-activin was injected subcutaneously in the middle third of the forearm every other day with 1.0 ml, No. 5; 2. UHF No. 7. 3. Outwardly: disinfectants.

Leishmania from the lesion disappeared on the 7th day of treatment. The number of bed days spent - 9. Discharged sick

Yo

00

6

4

 With

with clinical recovery. The ulcer completely healed, the infiltrate resolved.

P rome r 2. The patient is 19 years old. He entered the hospital of the Turkmen Republican Dermatovenerologic Dispensary with complaints of unhealed ulcers. The duration of the process is 2.5 months. Objectively: in the region of the right shoulder on the inner and outer surfaces there are two ulcers measuring 2.0x2.0 cm and 1.5x1.5 cm. They are superficial, islands of granulation tissue are visible at the bottom of the ulcer. In the direction of the axilla, along the lymphatic vessels are nodular lymphangitis (nodes up to 0.5 cm in diameter). Diagnosis: zoonotic cutaneous leishmaniasis in the scarring stage, complicated by multiple nodular lymphocytes. Treatment: T-activin - subcutaneously every other day, 1.0 ml in the middle third of the right shoulder, 3 injections per course2 External: disinfecting ointments. Leishmania from the lesion disappeared on the 6th day of treatment. It was discharged completely healthy. The ulcers healed, the nodes of the lymphangitis resorbed.

Example 3. Sick 66 years. She was admitted to the hospital of the Turkmen Research Institute of Skin Diseases with complaints of the presence of long non-healing ulcers. The process is 4 months old. In the area of the nose there is an ulcer 1.5x1.5 cm, covered with blood by a purulent-purulent crust. Around the link, as well as at a distance of 5-6 cm from it, there are multiple seed tubercles. Along the lymphatic vessels, there is nodular lymphangitis on the left cheek. Diagnosis: zoonotic cutaneous leishmaniasis in the scarring stage, complicated by multiple seeding tubercles, microabscesses, nodular lymphangitis and secondary pyococcal infection. The treatment was carried out: 1. T-activin subcutaneously every other day, 1.0 ml in the upper third of the left shoulder, No. 7.2. Outwardly: disinfecting ointments. It was spent in hospital 18 bed days. Leishmayii from the lesion disappeared on the 9th day from the start of treatment. The patient was discharged with clinical recovery, the ulcer healed, specific infiltrates resolved completely.

PRI me R 4. The patient is 22 years old. Entered

to the clinic of the Turkmen Research Institute of Skin Diseases with complaints of the presence of suppurable ulcers on the skin. Disease duration 2 months. Objectively: in the region of the lower third of the left forearm and on the skin of the face there are 2 ulcers

from 1.5 to 2.0 cm in diameter, covered with purulent crusts, from the first ulcer towards the axilla is nodular lymphangitis. Lymphangitis nodes up to 0.1 cm in diameter. Around both links there are seed tubercles. Diagnosis: zoonotic cutaneous leishmaniasis in the initial scarring stage complicated by nodular lymphangitis and semen tubercles. The treatment: 1. T-activin

subcutaneously every other day, 1.0 ml No. 6 in the middle third of the left shoulder. 2. Outwardly: disinfecting ointments. Held in hospital for 14 days. Leishmania disappeared from the lesion on the 9th day. The patient was discharged completely well. Ulcers healed, nodular lymphangitis resorbed by the end of treatment.

This method treated more than 40 patients with zoonotic dermal leishmaniasis.

in the second half of this disease. Moreover, in all cases, a complete clinical recovery was achieved. Observations of patients within 1-2 years after treatment showed the absence of relapse zoonozno

cutaneous leishmaniasis. The average number of hospitalized bed days was in the range of 12-20 days. All this indicates the effectiveness of the proposed method.

Claims (1)

The claims A method of treating zoonotic cutaneous leishmaniasis, comprising administering immunocorrective agents, characterized in that, in order to shorten the time treatment with the exclusion of antibiotic therapy, 1.0 T-activin in the form of a 0.01% solution is injected subcutaneously into the area located between the regional lymph nodes of the area of the main skin lesions.